378 results on '"Müllauer L"'
Search Results
2. 192P Analysis of tumor-associated macrophages and tumor-infiltrating lymphocytes within the tumor microenvironment of primary tumors and matched brain metastases
3. Applied precision cancer medicine in metastatic biliary tract cancer
4. Der Transkriptionsfaktor ARID1A als neuer, prognostischer Marker bei Patientinnen mit Endometriumkarzinom und NSMP-Subtyp
5. Kombinierte Chemo- und Immuntherapie bei fortgeschrittenen oder rezidivierten, PD-L1 positiven Vaginal- und Vulvarkarzinomen – eine Fallserie
6. Einfluss des molekularpathologischen Befundes auf Diagnose und Therapie: Fallbericht eines POLE-mutierten metastasierten Endometriumkarzinoms
7. 125P Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
8. PRECISION MEDICINE TUMOR BOARDS: APPLICABILITY OF PERSONALIZED TREATMENT CONCEPTS IN OVARIAN CANCER: EP861
9. CLINICAL IMPLICATIONS OF MOLECULAR PROFILING IN PATIENTS WITH PRIMARY ENDOMETRIAL CANCER: EP619
10. Programmed death-ligand 1 expression in rectal cancer
11. OS03.5.A Characterization of the inflammatory tumor microenvironment composition in solid cancer patients with brain metastases after progression to immune checkpoint inhibitor therapy
12. 450MO Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
13. PD-L1 als potentielles Therapieziel für eine Subgruppe muzinöser Ovarialkarzinome mit hypermutiertem Genotyp
14. ctDNA als prädiktiver Marker für postoperativen Tumorrest – eine Pilotstudie
15. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
16. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia
17. PD-L1 als potentielles Therapieziel für eine Subgruppe muzinöser Ovarial-karzinome mit hypermutiertem Genotyp
18. Hormonal Regulation of Hepatic Cell Proliferation and Apoptosis: Implications for Carcinogenesis
19. Active Cell Death and Cancer
20. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis
21. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
22. 20P Tissue agnostic application of mTOR inhibitors for the management of therapy-refractory solid tumors
23. Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
24. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients
25. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: A novel canine pan pre-B- and B-cell marker
26. 805P Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
27. 509P Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
28. Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma
29. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course
30. Expression of Vascular Endothelial Growth Factor and its Receptors in Canine Lymphoma
31. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites
32. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
33. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia
34. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis
35. Dermal infiltrates of cutaneous T-cell lymphomas with epidermotropism but not other cutaneous lymphomas are abundant with langerin+ dendritic cells
36. 10P Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma
37. 9P Gender and molecular aspects of molecular-guided therapy recommendations for therapy refractory head and neck cancers
38. 921P Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
39. 1953P Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumours: Data from the real-world precision medicine platform MONDTI
40. DNA damage repair gene alteration status as a predictive marker for response to neoadjuvant chemotherapy in muscle invasive bladder cancer
41. P-28 Impact of p-mTOR expression on molecular-guided therapy strategies in therapy-refractory metastatic pancreatic ductal adenocarcinoma
42. Vergleich der Detektionsraten von BRCA 1/2-Mutationen mittels Tumortestung versus Keimbahntestung bei Patientinnen mit epithelialem Ovarialkarzinom – eine retrospektive Datenanalyse
43. ctDNA beim Ovarialkarzinom
44. Identification of basophils as source of hepatocyte growth factor (HGF) in CML: A potential trigger of neoangiogenesis and autocrine growth involving c-MET: V649
45. Applied Precision Cancer Medicine in Neuro-Oncology
46. Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression
47. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry
48. Pathology and clinical course of MALT lymphoma with plasmacytic differentiation
49. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7
50. EP861 Precision medicine tumor boards: applicability of personalized treatment concepts in ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.